An open-label, parallel-group, bioavailability study to assess the pharmacokinetics of CAT-354 following subcutaneous and intravenous administration

Trial Profile

An open-label, parallel-group, bioavailability study to assess the pharmacokinetics of CAT-354 following subcutaneous and intravenous administration

Completed
Phase of Trial: Phase I

Latest Information Update: 09 May 2017

At a glance

  • Drugs Tralokinumab; Tralokinumab
  • Indications Asthma
  • Focus Pharmacokinetics
  • Sponsors MedImmune
  • Most Recent Events

    • 19 May 2009 Results reported at the 105th International Conference of the American Thoracic Society.
    • 15 Apr 2008 Dosing has begun according to a MedImmune media release.
    • 15 Apr 2008 Status changed from initiated to recruiting according to a MedImmune media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top